ACAD — Acadia Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $3.54bn
- $2.72bn
- $1.07bn
Annual income statement for Acadia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 484 | 517 | 726 | 958 | 1,072 |
| Cost of Revenue | |||||
| Gross Profit | 466 | 507 | 685 | 876 | 983 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 655 | 741 | 800 | 727 | 967 |
| Operating Profit | -170 | -224 | -73.4 | 231 | 105 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -168 | -213 | -51 | 258 | 139 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -168 | -216 | -61.3 | 226 | 391 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -168 | -216 | -61.3 | 226 | 391 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -168 | -216 | -61.3 | 226 | 391 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.05 | -1.34 | -0.374 | 0.588 | 2.3 |